Roche (OTCQX:RHHBY) unit Genentech initiates a
Phase 3 clinical trial, COVACTA, evaluating Actemra (tocilizumab) plus
standard-of-care (SOC) treatment versus placebo + SOC in hospitalized
adult patients with severe COVID-19 pneumonia.
The IL-6 receptor antagonist is currently approved
in the U.S. for rheumatoid arthritis, juvenile ideopathic arthritis,
giant cell arteritis and CAR T cell-induced cytokine release syndrome.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.